Issue 1
Two research needs around plasma p-tau217
Blood tests for Alzheimer's disease biology are being discussed because cerebrospinal fluid sampling and PET are hard to scale. That discussion is a research topic. It is not a clinic workflow.
This issue states two needs AlzBrief will keep returning to. The only source cited here is a Research Square preprint:
doi:10.21203/rs.3.rs-10410778/v1
Need 1. Read plasma p-tau217 with amyloid-β, not as a stamp
Plasma phosphorylated tau 217 (p-tau217) and amyloid-β (Aβ) markers are being studied together. They are not interchangeable stamps. The preprint above describes how those two plasma indices sit relative to each other across clinical groups, and it treats concordance and discordance as something to interpret.
That work is a preprint. It has not been peer-reviewed by a journal. The authors state that diagnoses were clinical, and that the analysis is agreement between two plasma indices rather than validation against an independent amyloid reference such as PET or CSF.
AlzBrief's first need is modest: research notes should keep both markers in view, and should say when a claim has not been checked against PET or CSF.
Need 2. Discordance is not a treatment license
When plasma p-tau217 and Aβ do not agree, that disagreement is a research problem. It is not a rule for treating, and it is not a rule for skipping PET, CSF, or MRI. The same preprint reports that discordant profiles were not resolved by a plasma total-tau reference interval, and it asks for prospective studies anchored to a reference standard.
AlzBrief will not put a browser tool on this site that turns a blood value into a posterior probability, a staging tier, or an eligibility decision. A blood test is not a license to treat. It is not a license to skip PET, CSF, or MRI. Even if a blood marker falls during treatment, that drop is not a license to skip follow-up amyloid PET.
Safety MRI during anti-amyloid therapy follows the Korean product label; this issue does not reprint that clock.
What this issue does not do
This issue does not invent enrollment figures, ARIA rates, or post-test probabilities. It does not replay a virtual professor. It does not upgrade gray-zone cases. qEEG and speech, and similar digital methods, are research methods only; they are not a judge that splits gray-zone cases or upgrades staging. Readers who want the underlying measurements should open the preprint.